CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 59 enrolled
Drug / intervention
Gana V® +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05215054
NCT05215054N/ACompleted
CompareCT.gov

Clinical Study for the Safety and Effectiveness of Use of an Injectable Medical Device GANA V® for Facial Aesthetic Treatment

GCS Co., Ltd·interventional·Posted Jan 31, 2022·Updated Jan 20, 2025

In Brief

A clinical study evaluating Gana V® and Sculptra® for Wrinkle. Completed, enrolled 59 participants across 1 site.

Detailed Summary

The purpose of this study is to assess the effectiveness and safety of Gana V, a Poly L-lactic acid filler for the aesthetic treatment of nasolabial folds, in comparison with Sculptra.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWrinkle
CountriesFrance
CollaboratorsEurofins Dermscan Pharmascan

Timeline

N/ACompletedFinished
20222023202420252026
First PostedJan 31, 2022
Enrollment StartMar 7, 2022
Primary CompletionNov 7, 2022
Study CompletionMay 7, 2024
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 4.4 years ago

Interventions

Gana V®device

Injection in the deep dermis and subcutaneous layer of the nasolabial fold on D0 (initial injection) and 1 month and a half after initial injection if necessary (optional touch-up).

Sculptra®device

Injection in the deep dermis and subcutaneous layer of the nasolabial fold on D0 (initial injection) and 1 month and a half after initial injection if necessary (optional touch-up).